Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $80 to $90.
Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $90
Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $80 to $90.
Related Posts
PNC Bank Acquires $16.6B Select Capital Commitments Facilities Of Signature Bridge Bank
PNC Financial Services Group Inc's (NYSE: PNC) PNC Bank disclosed buying a portfolio of select capital
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.
Tesla Bull Says EV Giant Already Has A $25K Car: ‘It’s Called A Used Model Y’
Ross Gerber, the President and CEO of Gerber Kawasaki Wealth and Investment Management and a Tesla bull, said on Friday that the company already has a $25,000 car — it's called a used Model Y.